Acquisition of Cialis brand rights in three Asian markets.
This acquisition strengthens Zuellig Pharma's position in the Asian pharmaceutical market by expanding its portfolio of owned prescription products. It demonstrates a strategic move to gain greater control over key brands and enhance market access for important treatments like Cialis, which addresses common health concerns such as erectile dysfunction and benign prostatic hyperplasia. The expansion to 11 markets signifies a significant step in their regional growth strategy and commitment to making healthcare more accessible.
The acquisition specifically targets markets in East Asia (Hong Kong, Macau, South Korea), indicating a focused expansion strategy within the region. This move is significant given the growing demand for pharmaceutical products and healthcare solutions across Asia.
This expands their owned brand portfolio to 11 Asian markets.
The acquisition supports their strategy to increase access to prescription healthcare products.
Zuellig Pharma acquired Cialis rights in Hong Kong, Macau, and South Korea.
This expands their owned brand portfolio to 11 Asian markets.
The acquisition supports their strategy to increase access to prescription healthcare products.
Zuellig Pharma 已从礼来公司手中收购了 Cialis（他达拉非）在香港、澳门和韩国的所有权利。此次扩张使 Zuellig Pharma 在亚洲的品牌所有权扩展到 11 个市场。此举符合公司建立强大自有处方保健产品组合的战略重点，旨在扩大对治疗勃起功能障碍和良性前列腺增生药物的可及性。
登录后可保存信号笔记。
登录